| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
|
Foster, Scott A.
|
|
2016
|
29 |
4 |
p. 477-493
17 p.
|
article
|
| 2 |
A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity
|
Jing, Hui
|
|
2016
|
29 |
4 |
p. 607-
1 p.
|
article
|
| 3 |
Blood-Brain Barrier Breakdown Determines Differential Therapeutic Outcome in Genetically Diverse Forms of Medulloblastoma
|
Guerit, Sylvaine
|
|
2016
|
29 |
4 |
p. 427-429
3 p.
|
article
|
| 4 |
Defining and Targeting the Oncogenic Drivers of Neuroendocrine Prostate Cancer
|
Carver, Brett S.
|
|
2016
|
29 |
4 |
p. 431-432
2 p.
|
article
|
| 5 |
Deletion Mutations Keep Kinase Inhibitors in the Loop
|
Freed, Daniel M.
|
|
2016
|
29 |
4 |
p. 423-425
3 p.
|
article
|
| 6 |
Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs
|
Brien, Gerard L.
|
|
2016
|
29 |
4 |
p. 464-476
13 p.
|
article
|
| 7 |
Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression
|
Bueno, María J.
|
|
2016
|
29 |
4 |
p. 607-608
2 p.
|
article
|
| 8 |
Glycoholics Anonymous: Cancer Sobers Up with mTORC1
|
Fu, Vivian
|
|
2016
|
29 |
4 |
p. 432-434
3 p.
|
article
|
| 9 |
Interfering with CCL5/CCR5 at the Tumor-Stroma Interface
|
Bronte, Vincenzo
|
|
2016
|
29 |
4 |
p. 437-439
3 p.
|
article
|
| 10 |
Intratumoral Heterogeneity of the Epigenome
|
Mazor, Tali
|
|
2016
|
29 |
4 |
p. 440-451
12 p.
|
article
|
| 11 |
Kicking Genomic Profiling to the Curb: How Re-wiring the Phosphoproteome Can Explain Treatment Resistance in Glioma
|
Lam, Fred C.
|
|
2016
|
29 |
4 |
p. 435-436
2 p.
|
article
|
| 12 |
Killing Lymphoma with Smac-Mimetics: As Easy as ABC?
|
Nachbur, Ueli
|
|
2016
|
29 |
4 |
p. 425-427
3 p.
|
article
|
| 13 |
Long Noncoding RNAs in Cancer Pathways
|
Schmitt, Adam M.
|
|
2016
|
29 |
4 |
p. 452-463
12 p.
|
article
|
| 14 |
Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype
|
Phoenix, Timothy N.
|
|
2016
|
29 |
4 |
p. 508-522
15 p.
|
article
|
| 15 |
miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells
|
Lechman, Eric R.
|
|
2016
|
29 |
4 |
p. 602-606
5 p.
|
article
|
| 16 |
mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells
|
Pusapati, Raju V.
|
|
2016
|
29 |
4 |
p. 548-562
15 p.
|
article
|
| 17 |
N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells
|
Lee, John K.
|
|
2016
|
29 |
4 |
p. 536-547
12 p.
|
article
|
| 18 |
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma
|
Wei, Wei
|
|
2016
|
29 |
4 |
p. 563-573
11 p.
|
article
|
| 19 |
SnapShot: Renal Cell Carcinoma
|
Ricketts, Christopher J.
|
|
2016
|
29 |
4 |
p. 610-610.e1
5491 p.
|
article
|
| 20 |
Spontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms
|
Wang, Qi
|
|
2016
|
29 |
4 |
p. 523-535
13 p.
|
article
|
| 21 |
Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma
|
Yang, Yibin
|
|
2016
|
29 |
4 |
p. 494-507
14 p.
|
article
|
| 22 |
Targeting PI3K Signaling in Cancer: A Cautionary Tale of Two AKTs
|
Fortin, Jérôme
|
|
2016
|
29 |
4 |
p. 429-431
3 p.
|
article
|
| 23 |
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
|
Townsend, Elizabeth C.
|
|
2016
|
29 |
4 |
p. 574-586
13 p.
|
article
|
| 24 |
Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients
|
Halama, Niels
|
|
2016
|
29 |
4 |
p. 587-601
15 p.
|
article
|
Journal description